CSF1 and neoplasm: Many inhibitors, such as inhibitors of ANG2 (Trebananib), CCL2/CCR2 (Carlumab and PF-04136309), CCL5/CCR5 (Leronlimab, Maraviroc, and Maraviroc), CSF-1/CSF-1R (Emactuzumab and Pexidartinib), and VEGF have been shown to inhibit macrophage recruitment for tumor growth.404